EGFR

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTK). These trans-membrane proteins are activated following binding with peptide growth factors of the EGF-family of proteins. Evidence suggests that the EGFR is involved in the pathogenesis and progression of different carcinoma types. The EGFR and EGF-like peptides are often over-expressed in human carcinomas. Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including squamous-cell carcinoma of the lung (80% of cases), anal cancers, glioblastoma (50%) and epithelian tumors of the head and neck (80-100%).

EGFR Associated Disease
  • CAR Vector Products

  • AbTCR Vector Products

  • CAR Cell Products

  • CAR Viral Particles

  • DMAb

  • Protein

  • TriCAR Vector Products

  • TCR-Like CAR

  • CAR-MA Vector Products

  • CAR-MA Cell Products

  • CAR Animal Cells

  • CAR mRNA

  • TCR-Like Antibody

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
  • CAR Vector Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-ZP8476 A uniCAR [Anti-FITC CAR], with a mAb-based CAR Adaptor [Anti-EGFR (Cetuximab)], a Switchable CAR System Breast cancer Lentiviral vector   Add to Cart   Datasheet
CAR-ZP8493 A uniCAR [Anti-CD16 CAR], with a mAb-based CAR Adaptor [Anti-EGFR (Cetuximab)], a Switchable CAR System Breast cancer Lentiviral vector   Add to Cart   Datasheet
CAR-ZP8494 A uniCAR [Anti-CD16 CAR], with a mAb-based CAR Adaptor [Anti-EGFR (Panitumumab)], a Switchable CAR System Breast cancer Lentiviral vector   Add to Cart   Datasheet
XS-0323-LX29 Anti-EGFR VHH(X3XH29) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector Human X3XH29 VHH-CD28-41BB-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX30 Anti-EGFR VHH(X3XH30) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector Human X3XH30 VHH-CD28-41BB-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX31 Anti-EGFR VHH(X3XH31) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector Human X3XH31 VHH-CD28-41BB-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX36 Anti-EGFR VHH(X3XH36) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector Human X3XH36 VHH-CD28-41BB-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX37 Anti-EGFR VHH(X3XH37) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector Human X3XH37 VHH-CD28-41BB-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX38 Anti-EGFR VHH(X3XH38) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 Vector Human X3XH38 VHH-CD28-41BB-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX385 Anti-EGFR VHH(X3XH16) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector Human X3XH16 VHH-ICOS-4-1BB-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX393 Anti-EGFR VHH(X3XH24) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector Human X3XH24 VHH-ICOS-4-1BB-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX394 Anti-EGFR VHH(X3XH25) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector Human X3XH25 VHH-ICOS-4-1BB-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX395 Anti-EGFR VHH(X3XH26) h(ICOS-41BB-CD3ζ) CAR, pCDCAR1 Vector Human X3XH26 VHH-ICOS-4-1BB-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX741 Anti-EGFR VHH(X3XH3) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector Human X3XH3 VHH-CD28-OX40-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX742 Anti-EGFR VHH(X3XH4) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector Human X3XH4 VHH-CD28-OX40-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX743 Anti-EGFR VHH(X3XH5) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector Human X3XH5 VHH-CD28-OX40-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX744 Anti-EGFR VHH(X3XH6) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector Human X3XH6 VHH-CD28-OX40-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX750 Anti-EGFR VHH(X3XH12) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector Human X3XH12 VHH-CD28-OX40-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX751 Anti-EGFR VHH(X3XH13) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector Human X3XH13 VHH-CD28-OX40-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX752 Anti-EGFR VHH(X3XH14) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector Human X3XH14 VHH-CD28-OX40-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX771 Anti-EGFR VHH(X3XH33) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector Human X3XH33 VHH-CD28-OX40-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX772 Anti-EGFR VHH(X3XH34) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector Human X3XH34 VHH-CD28-OX40-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
XS-0323-LX777 Anti-EGFR VHH(X3XH39) h(CD28-OX40-CD3ζ) CAR, pCDCAR1 Vector Human X3XH39 VHH-CD28-OX40-CD3ζ Lentiviral vector T cell CAR-T   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.